Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

213 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) is a novel marker for patients with BRAF-mutated metastatic melanoma.
Audrito V, Managò A, Zamporlini F, Rulli E, Gaudino F, Madonna G, D'Atri S, Antonini Cappellini GC, Ascierto PA, Massi D, Raffaelli N, Mandalà M, Deaglio S. Audrito V, et al. Among authors: deaglio s. Oncotarget. 2018 Apr 10;9(27):18997-19005. doi: 10.18632/oncotarget.24871. eCollection 2018 Apr 10. Oncotarget. 2018. PMID: 29721178 Free PMC article.
PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics.
Massi D, Brusa D, Merelli B, Ciano M, Audrito V, Serra S, Buonincontri R, Baroni G, Nassini R, Minocci D, Cattaneo L, Tamborini E, Carobbio A, Rulli E, Deaglio S, Mandalà M. Massi D, et al. Among authors: deaglio s. Ann Oncol. 2014 Dec;25(12):2433-2442. doi: 10.1093/annonc/mdu452. Epub 2014 Sep 15. Ann Oncol. 2014. PMID: 25223485 Free article.
Extracellular nicotinamide phosphoribosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic lymphocytic leukemia.
Audrito V, Serra S, Brusa D, Mazzola F, Arruga F, Vaisitti T, Coscia M, Maffei R, Rossi D, Wang T, Inghirami G, Rizzi M, Gaidano G, Garcia JG, Wolberger C, Raffaelli N, Deaglio S. Audrito V, et al. Among authors: deaglio s. Blood. 2015 Jan 1;125(1):111-23. doi: 10.1182/blood-2014-07-589069. Epub 2014 Nov 3. Blood. 2015. PMID: 25368373 Free article.
The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600.
Massi D, Brusa D, Merelli B, Falcone C, Xue G, Carobbio A, Nassini R, Baroni G, Tamborini E, Cattaneo L, Audrito V, Deaglio S, Mandalà M. Massi D, et al. Among authors: deaglio s. Ann Oncol. 2015 Sep;26(9):1980-1987. doi: 10.1093/annonc/mdv255. Epub 2015 Jun 2. Ann Oncol. 2015. PMID: 26037795 Free article.
213 results